Alpine Immune Sciences, Inc.

NasdaqGM:ALPN Voorraadrapport

Marktkapitalisatie: US$4.5b

Alpine Immune Sciences Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Alpine Immune Sciences heeft een totaal eigen vermogen van $332.7M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $373.6M en $40.9M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsration/a
ContantUS$305.66m
AandelenUS$332.70m
Totaal verplichtingenUS$40.94m
Totaal activaUS$373.65m

Recente financiële gezondheidsupdates

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21
Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19
Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23
We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

May 11
Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Dec 12
Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Sep 20

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09
Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12
Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18
Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18
Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $308.3M ) ALPN } overtreffen de korte termijn passiva ( $32.2M ).

Langlopende schulden: De kortetermijnactiva ALPN ( $308.3M ) overtreffen de langetermijnschulden ( $8.7M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: ALPN is schuldenvrij.

Schuld verminderen: ALPN heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 6.6% was.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: ALPN heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: ALPN heeft voldoende kasruimte voor 2.4 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 21.4 % per jaar.


Ontdek gezonde bedrijven